

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Masaji ISHIOGUCHI, et al.

GROUP ART UNIT: 1202

SERIAL NUMBER: 08/722,144

EXAMINER:

FILED: December 12, 1996

FOR: PENEM DERIVATIVES AND ANTIMETABOLIC AGENT CONTAINING THE SAME

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.97

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:  
Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The Applicant(s) wish to make of record the references listed on the attached Form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☒ A check is attached in the amount required under 37 CFR § 1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending applications or issued patents which may be related to the present application. A copy of the patent(s) is attached along with PTO 1449.
- ☐ A check is attached in the amount required under 37 CFR § 1.17(p).

CERTIFICATION

The undersigned certifies that

- ☐ each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ no item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR § 1.56(c) more than three months prior to the filing of this statement.

PETITION

- ☐ Applicant(s) hereby request consideration of the attached information. A check is attached in the amount of the Petition fee required under 37 CFR § 1.17(i)(1).

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account No. 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.



Norman F. Oblon  
Attorney of Record  
Registration No. 24,618  
010 IL 05/29/97 08722144  
1-128 230.00 CK

Fourth Floor  
1755 Jefferson Davis Highway  
Arlington, Virginia 22202  
(703) 413-3000  
Fax No. (703) 413-2220  
(OSMMN 1/97)

John K. Pike, Ph.D.  
Registration No. 41,253

Docket No.: 2292-038-0 PC

Serial No.: 08/722,144



Sheet 1 of 1

Group Art Unit: 1205A

STATEMENT OF RELEVANCY

JUN 2 1997

Reference AL (JP 4 69387) on Form 1449:

This reference discloses only a preparation process of a 5,6-cis-penem derivative, which features exposure of a corresponding 5,6-trans-penem derivative to radiation of light.

Reference AR on Form 1449:

This reference relates to synthesis of penem derivatives. Concerning their antimicrobial properties, it is disclosed that the trans isomers have antimicrobial properties but the cis isomers have no significant antimicrobial properties.